Organization
Indiana University Simon Comprehensive Cancer Center
23 abstracts
Abstract
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.Org: Department of Urologic Sciences, Vancouver General Hospital, Canada, BC Cancer - Vancouver Centre, BC,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
Exploring health disparities in prostate cancer through circulating tumor DNA analysis.Org: Indiana University School of Medicine, Indiana University Simon Comprehensive Cancer Center,
Abstract
Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?Org: Indiana University School of Medicine, Indiana University Health, Indiana University Simon Comprehensive Cancer Center,
Abstract
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis,
Abstract
A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indiana University Melvin and Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis,
Abstract
Xerostomia and ocular dryness as predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.Org: Indiana University Simon Comprehensive Cancer Center,
Abstract
Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (LSCC) with use of immune checkpoint inhibitors (ICIs).Org: Indiana University Melvin and Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, IU Simon Cancer Center,
Abstract
Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma.Org: Indiana University – Purdue University Indianapolis, Indiana University Simon Comprehensive Cancer Center, IU Simon Cancer Center, Indiana University Simon Cancer Center and Roudebush VAMC,
Abstract
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.Org: BCCancer, Multicare Auburn Medical Center, Intermountain Healthcare, Indiana University Simon Comprehensive Cancer Center, Center for Data Intensive Science at the University of Chicago,
Abstract
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, Barbara Ann Karmanos Cancer Institute, Indiana University Simon Comprehensive Cancer Center,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Abstract
Multimodality, online oncology learning resources: Meeting residents where they are—A pilot to create a new oncology curriculum.Org: Indiana University Simon Comprehensive Cancer Center, Indiana University Internal Medicine, Indiana University – Purdue University Indianapolis, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN,
Abstract
Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals,
Abstract
Clostridium difficile infection and immune mediated diarrhea and colitis in patients with cancer on immune checkpoint inhibitors.Org: Indiana University – Purdue University Indianapolis, Mayo Clinic Rochester, Rochester, MN, Indiana University Simon Comprehensive Cancer Center,
Abstract
Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.Org: Indiana University Simon Comprehensive Cancer Center,
Abstract
A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Nebraska Cancer Specialists - Midwest Cancer Center, Rush University Medical Center,
Abstract
The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals, Indiana University School of Medicine Department of Medicine, IU Hematology/Oncology,
Abstract
Trends of female representation in ASCO leadership and abstracts authorship: A detailed review.Org: Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis,
Abstract
The SMILE scale: A pilot study among patients with cancer.Org: IU Simon Cancer Center, Indiana University School of Medicine Department of Medicine, Indiana University – Purdue University Indianapolis, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center,